Evidence map›Paper›PMID 30815994›Full record

Observational studyESC heart failure2019

Peritoneal dialysis as therapeutic option in heart failure patients.

Leonie Grossekettler, Bastian Schmack, Katrin Meyer, Carsten Brockmann, Reinhard Wanninger, Michael M Kreusser, Lutz Frankenstein, Lars P Kihm, Martin Zeier, Hugo A Katus and 2 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in ESC heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06326996 (Thiamine Intervention and Cognition in Older Adults Undergoing Coronary Artery Bypass Grafting - A Randomized Clinical Trial.), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06326996 early_phase1recruitingnot on this mapstarted 2024, after this paper: background citation

Thiamine Intervention and Cognition in Older Adults Undergoing Coronary Artery Bypass Grafting - A Randomized Clinical Trial.

TypeinterventionalSponsorUniversity of California, Los AngelesRan2024 to 2026Enrolled52ConditionsCoronary Heart Disease, Coronary Artery Bypass GraftingArmsThiamine, Placebo
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Peritoneal dialysis and heart failure.Current opinion in nephrology and hypertension · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Heart Failure-Focus on Kidney Replacement Therapy: Why, When, and How?International journal of molecular sciences · 2025
    Review
  7. The cardiovascular unphysiology of thrice weekly hemodialysis.Current opinion in nephrology and hypertension · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Kidney Replacement Therapy in Cardiorenal Syndromes.Journal of clinical medicine research · 2022
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Observational
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Leonie GrossekettlerDepartment of Internal Medicine III, Cardiology, Angiology and Pulmonology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Bastian SchmackClinic for Cardiac Surgery, University Hospital of Heidelberg, Heidelberg, Germany.
Katrin MeyerClinic for Cardiology, Heart and Vascular Center, Bad Bevensen, Germany.
Carsten BrockmannDepartment of Nephrology, Medical Center, Bad Bevensen, Germany.
Reinhard WanningerDepartment of Nephrology, Clinic Braunschweig, Braunschweig, Germany.
Michael M KreusserDepartment of Internal Medicine III, Cardiology, Angiology and Pulmonology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Lutz FrankensteinDepartment of Internal Medicine III, Cardiology, Angiology and Pulmonology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Lars P KihmDepartment of Internal Medicine I, Endocrinology and Nephrology, University Hospital of Heidelberg, Heidelberg, Germany.
Martin ZeierDepartment of Internal Medicine I, Endocrinology and Nephrology, University Hospital of Heidelberg, Heidelberg, Germany.
Hugo A KatusDepartment of Internal Medicine III, Cardiology, Angiology and Pulmonology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Andrew RemppisClinic for Cardiology, Heart and Vascular Center, Bad Bevensen, Germany.
Vedat SchwengerDepartment of Internal Medicine I, Endocrinology and Nephrology, University Hospital of Heidelberg, Heidelberg, Germany.
University Hospital Heidelberg · DEHeidelberg University · DEKlinik Lüneburger Heide · DETechnische Universität Braunschweig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsEach episode of acute decompensated heart failure (HF) incrementally adds to mortality. Peritoneal dialysis (PD) offers an alternative therapeutic option in refractory HF and reduces the incidence of decompensation episodes. The objective of this study was to determine the efficacy of PD, in terms of functional status, surrogate endpoints, rate of hospitalizations, and mortality. METHODS AND

resultsThis study is based on the registry of the German Society of Nephrology, involving 159 patients receiving PD treatment due to refractory HF between January 2010 and December 2014. Body weight was reduced by PD (82.2 ± 14.9 to 78.4 ± 14.8 kg, P < 0.001), and significant improvements in New York Heart Association functional class (3.38 ± 0.55 to 2.85 ± 0.49, P < 0.001) were found already after 3 months. Left ventricular ejection fraction did not change (31.5 ± 13.8 to 34.0 ± 15.7%, P = 0.175). C-reactive protein improved with PD treatment (33.7 ± 52.6 to 17.1 ± 26.3 mg/L, P = 0.004). Blood urea nitrogen/creatinine ratio decreased significantly (148.7 ± 68.3 to 106.7 ± 44.8 mg/dL, P < 0.001). Hospitalization rates decreased significantly (total number 2.86 ± 1.88 to 1.90 ± 1.78, P = 0.001, and 39.2 ± 30.7 to 27.1 ± 25.2 days, P = 0.004). One year mortality was 39.6% in end-stage HF patients treated with PD.

conclusionsPeritoneal dialysis offers an additional therapeutic option in end-stage HF and is associated with improved New York Heart Association classification and reduced hospitalization. Although PD treatment was associated with various benefits, further studies are necessary to identify which patients benefit the most from PD.

Indexed as

RegistriesAcute DiseaseAgedFemaleFollow-Up StudiesGermanyHeart FailureHumansMalePeritoneal DialysisProspective StudiesStroke VolumeSurvival RateTime FactorsTreatment OutcomeCardiorenal syndromeHeart failurePeritoneal dialysisUltrafiltration

Identifiers

PMID30815994
PMCPMC6437425
OpenAlexW2918706955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.